|MDACC Study No:||2013-0315 (clinicaltrials.gov NCT No: NCT01889186)|
|Title:||A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with|
Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion
|Principal Investigator:||William G. Wierda|
|Treatment Agent:||ABT-199 |
|Study Description:||The goal of this clinical research study is to learn if ABT-199 can help to |
control CLL in patients who have an abnormal gene called a 17p deletion and
its safety. The tolerability of ABT-199 will also be studied.